Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the rat

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 3, 2003, Pages 201-212

  Webber, C ^a   Stokes, C A ^a   Persiani, S ^b   Makovec, F ^b   McBurney, A ^a   Kapil, R P ^c   John, B A ^a   Houchen, T L ^a   D'Amato, M ^b   Chasseaud, L F ^a  

^a HUNTINGDON LIFE SCIENCES   (United Kingdom)

^b Rotta Research Laboratorium   (Italy)

^c FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Cholecystokinin antagonist; Dexloxiglumide; Metabolism; Pharmacokinetics; Rats

Indexed keywords

ALCOHOL; CARBON 14; CARBOXYLIC ACID; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEXLOXIGLUMIDE; DRUG METABOLITE; PLASMA PROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; DEMETHYLATION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; DRUG URINE LEVEL; ENTEROHEPATIC CIRCULATION; FECES; FEMALE; KIDNEY CLEARANCE; LIQUID CHROMATOGRAPHY; LIVER CLEARANCE; MALE; MASS SPECTROMETRY; NONHUMAN; RAT; SEX DIFFERENCE;

EID: 10744233931     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190486     Document Type: Article

References (23)

1. Woodruff G.N. and Hughes J. (1991): Cholecystokinin antagonists. Ann.Rev.Pharmacol.Toxicol., 31,469-501.
2. D'Amato M., Makovec F., Rovati L.C. (1999b): CCKA-receptors in gastrointestinal disorders. Drug Development: Molecular Targets for GI Diseases, edited by T.S. Gaginella and A. Guglietta, (Totowa, NJ: Human Press) pp.147-175.
3. Grider J.R. (1994): Role of cholecystokinin in the regulation of gastrointestinal motility. J.Nutrit., 124 (Suppl. 8), 1334S-1339S.
4. Revel L., Makovec F., Castaner J. (1999): Dexloxiglumide - CCK1 (CCKA) receptor antagonist treatment of irritable bowel syndrome. Drugs of the Future, 24, 725-728.
5. Scarpignato C., Kisfalvi I., D'Amato M., and Varga G. (1996): Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Alimen.Pharmacol.Ther., 10, 411-419.
6. Fioramonti J., D'Amato M., Rovati L., Buéno L. (1996): Effects of dexioxigiumide on gastric emptying delayed by colonic distension in dogs. Neurogastroenterol.Motil., 8, 172.
7. Rouzade M.L., Fiorarnonti J., D'Amato M., Rovati L., Buéno, L. (1996): Inhibitory action of dexloxiglumide on transient lower oesophageal sphincter relaxation in dogs. Neurogastroenterol.Motil., 8, 188.
8. Meier R., Beglinger C., Giacovelli G., D'Amato M. (1997): Effect of the CCK-A receptor antagonist dexloxiglumide on postprandial gallbladder emptying and colonic transit time in healthy volunteers, Gastroenterol., 112, A788.
9. D'Amato M., Whorwell P.J., Thompson D.G., Spiller R.C., Giacovelli G., Rovati L.C., (1999a): The efficacy and safety of the CCKA-receptor antagonist dexloxiglumide in IBS. Gut, 45 (Suppl.V), A258.
10. D'Amato M., Whorwell P.J., Thompson D.G., Spiller R.C., Giacovelli G., Griffin P.H., Schneier H. and Rovati L.C. (2001): CCK1-receptor antagonist dexloxiglumide is effective and safe in female patients with constipation predominant irritable bowel syndrome. Amer.J.Gastroenterol., 96, S317.
11. Feinle C., Meier O., D'Amato M. (1999): CCK-A Receptor blockade improves dyspeptic symptoms due to duodenal lipid and gastric distension in functional dyspepsia. Gastroenterol., 116, (Suppl.), A992.
12. Webber C., Roth A., Persiani S., Peard A.J., Makovec A., John B.A., Holding J.D., Hackett A.M., D'Amato M., Cybulski Z.R. and Chasseaud L.F. (2002): Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects. Drug Metab.Rev., 34, (Suppl.1), 79.
13. Webber C., Roth A., Persiani S., Peard A.J., Makovec A., Kapil R.P., John B.A., Holding J.D., D'Amato M., Cybulski Z.R., Chasseaud L.F. and Rovati L.C. (2003): Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects. Xenobiotica, 33, 625-641.
14. Ullberg S. and Larsson B. (1981): Whole-body autoradiography. In Progress in Drug Metabolism, edited by J.W. Bridges and L.F. Chasseaud (Chichester; Wiley), vol. 6, 249-289.
15. Davies B. and Morris T. (1993): Physiological parameters in laboratory animals and humans. Pharm.Res., 10, 1093-1095.
16. Waxman D.J., Dannan G.A. and Guengerich F.P. (1985): Regulation of rat hepatic cytochrome P-450: age dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isozymes. Biochemistry, 24, 4409-4417.
17. Skett P., (1987): Hormonal regulation and sex differences of xenobiotic metabolism. In Progress in Drug Metabolism, edited by J.W. Bridges, L.F. Chasseaud and G.G. Gibson, (London: Taylor and Francis), vol. 10, 85-140.
18. Hucker H.B., Kwan K.C., Duggan D.E. (1980): Pharmacokinetics and metabolism of non-steroidal anti-inflammatory agents. In Progress in Drug Metabolism, edited by J.W. Bridges and L.F. Chasseaud, (Chichester: Wiley), vol. 5, 165-253.
19. Hirom P.C., Idle J.R. and Millburn P. (1977): Comparative aspects of the biosynthesis and excretion of xenobiotic conjugates by non-primate mammals. In Drug Metabolism - From Microbe to Man, edited by D.V. Parke and R.L Smith, (London: Taylor and Francis), 299-329.
20. Okuda S. and Matsuzawa T. (1970): Absorption, distribution, excretion and metabolism of D,L-4-Benzarnide-N,N-di-n-propyl-glutaramic acid (proglumide) in rats. J. Takeda Res. Lab., 29, 93-101.
21. Gibson G.G. and Skett P. (1986): Introduction to Drug Metabolism, (London: Chapman and Hall).
22. Chasseaud L.F. and Hawkins D.R. (1990): Biotransformation of drugs. In Encyclopedia of Pharmaceutical Technology, edited by J. Swarbrick and J.C. Boylan, (New York: Marcel Dekker), 129-157.
23. Fieser L.F. and Fieser M. (1956): Organic Chemistry, (New York: Reinhold Publishing Corporation).